Ikena Oncology, Inc. (IKNA)

Ikena Oncology Statistics

Total Valuation

Ikena Oncology has a market cap or net worth of $83.00 million. The enterprise value is -$53.32 million.

Market Cap	83.00M
Enterprise Value	-53.32M

Important Dates

The next estimated earnings date is Friday, November 15, 2024, before market open.

Earnings Date	Nov 15, 2024
Ex-Dividend Date	n/a

Share Statistics

Ikena Oncology has 48.26 million shares outstanding. The number of shares has increased by 26.88% in one year.

Shares Outstanding	48.26M
Shares Change (YoY)	+26.88%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.52%
Owned by Institutions (%)	24.47%
Float	13.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	43.81
Forward PS	n/a
PB Ratio	0.58
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 18.22, with a Debt / Equity ratio of 0.06.

Current Ratio	18.22
Quick Ratio	17.74
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -44.54% and return on invested capital (ROIC) is -28.77%.

Return on Equity (ROE)	-44.54%
Return on Assets (ROA)	-27.41%
Return on Capital (ROIC)	-28.77%
Revenue Per Employee	$42,884
Profits Per Employee	-$1.55M
Employee Count	43
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	-73,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -60.91% in the last 52 weeks. The beta is 0.49, so Ikena Oncology's price volatility has been lower than the market average.

Beta (5Y)	0.49
52-Week Price Change	-60.91%
50-Day Moving Average	1.71
200-Day Moving Average	1.56
Relative Strength Index (RSI)	54.77
Average Volume (20 Days)	45,038

Short Selling Information

The latest short interest is 147,782, so 0.31% of the outstanding shares have been sold short.

Short Interest	147,782
Short Previous Month	207,127
Short % of Shares Out	0.31%
Short % of Float	1.07%
Short Ratio (days to cover)	3.87

Income Statement

In the last 12 months, Ikena Oncology had revenue of $1.84 million and -$66.71 million in losses. Loss per share was -$1.42.

Revenue	1.84M
Gross Profit	-47.44M
Operating Income	-72.20M
Pretax Income	-66.78M
Net Income	-66.71M
EBITDA	-71.34M
EBIT	-72.20M
Loss Per Share	-$1.42

Balance Sheet

The company has $145.42 million in cash and $9.09 million in debt, giving a net cash position of $136.33 million or $2.82 per share.

Cash & Cash Equivalents	145.42M
Total Debt	9.09M
Net Cash	136.33M
Net Cash Per Share	$2.82
Equity (Book Value)	142.86M
Book Value Per Share	2.96
Working Capital	141.13M

Cash Flow

In the last 12 months, operating cash flow was -$72.62 million and capital expenditures -$262,000, giving a free cash flow of -$72.88 million.

Operating Cash Flow	-72.62M
Capital Expenditures	-262,000
Free Cash Flow	-72.88M
FCF Per Share	-$1.51

Margins

Gross Margin	n/a
Operating Margin	-3,915.18%
Pretax Margin	-3,621.53%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-3,939.43%

Dividends & Yields

Ikena Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-26.88%
Shareholder Yield	-26.88%
Earnings Yield	-80.37%
FCF Yield	-87.81%

Analyst Forecast

The average price target for Ikena Oncology is $3.00, which is 74.42% higher than the current price. The consensus rating is "Buy".

Price Target	$3.00
Price Target Difference	74.42%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	36.14%
EPS Growth Forecast (5Y)	-12.74%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ikena Oncology has an Altman Z-Score of 1.77 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.77
Piotroski F-Score	1